Anyone who need to download this file can request by providing the email.

1. Group 3
Pharmaceutical Industries

2. Novartis International AG
Novartis was created
in 1996 from the Type Public AG
merger of Ciba- SIX: NOVN, NYSE: NVS
Geigy and Sandoz Industry Pharmaceuticals
Laboratories, both Founded 1996 (from merger)
Swiss companies Headquarters Basel, Switzerland
with long histories.
Key people Daniel Vasella (Chairman),Joseph
Ciba-Geigy was Jimenez (CEO)
formed in 1970 by Products Pharmaceuticals, generic
the merger of J. R. drugs, over-the-counter
Geigy Ltd (founded drugs, vaccines, diagnostics,contact
in Basel in 1758) lenses, animal health(list...)
and CIBA (founded Revenue US $50.624 billion (2010)
in Basel in 1859). Operating income US $11.526 billion (2010)
Combining the Net income US $9.969 billion (2010)
histories of the
Total assets US $123.32 billion (end 2010)
merger partners, the
Total equity US $69.769 billion (end 2010)
company's effective
history spans 250 Employees 119,418 (FTE, end 2010)
years Subsidiaries Ciba Vision, Sandoz, Alcon
Website novartis.com

3. Mission
We want to discover, develop and successfully market innovative products to
prevent and cure diseases, to ease suffering and to enhance the quality of
life.
We also want to provide a shareholder return that reflects outstanding
performance and to adequately reward those who invest ideas and work in
our company.
Research and development
The major bases for R&D are Basel, Shanghai,
and Boston. Operations in China are set for rapid expansion
within the next five years.
Major therapeutic areas are
autoimmunity/transplantation/inflammatory disease,
cardiovascular disease, diabetes, gastrointestinal disease,
infectious diseases, musculoskeletal disease, neuroscience,
oncology, ophthalmology, and respiratory disease.

5. Stakeholder
prevent and cure diseases
Full range of healthcare options enhance the quality of life. Outcomes
Prevention Drivers
Self-care
Innovative medicines Affordable options
Manufacturing
Internal Process
Distribution
Marketing Outcomes
Drivers
Learning & Growth
Cardiovascular and Metabolism Oncology
Respiratory
Immunology and Infectious Diseases Neuroscience and Ophthalmics Outcomes
Rejuvenate the Pharmaportfolio Build world-leading platform in eye care Drivers
Accelerate growth of non-Pharma businesses Focused diversification in healthcare
Expand in high-growth markets Strengthening franchises with specific needs
Investments
Outcomes
Drivers
Vaccines and Diagnostics
Pharmaceuticals Consumer Health (OTC, Animal Health and CIBA Vision)

6. Objective Description Measure Target Initiative